Process Development, Manufacture, and Understanding of the Atropisomerism and Polymorphism of Verinurad-Reference-Cited by-同舟云学术

Process Development, Manufacture, and Understanding of the Atropisomerism and Polymorphism of Verinurad

Published:2021-10-25 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Ring Oliver T.¹^ORCID,Hayter Barry R.¹,Ronson Thomas O.¹^ORCID,Agnew Lauren R.¹,Ashworth Ian W.¹^ORCID,Cherryman Janette¹,Gall Malcolm A. Y.¹^ORCID,Hamilton Peter R.¹,Inglesby Phillip A.¹^ORCID,Jones Martin F.¹,Lamacraft Alex L.¹,Leahy Adam J.¹,McKinney David¹,Miller-Potucka Lucie¹,Powell Lyn¹,Putra Okky D.²^ORCID,Robbins Andrew J.¹,Tomasi Simone¹^ORCID,Wordsworth Rosemary A.¹

Affiliation:

1. Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom

2. Early Product Development and Manufacturing, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00284

Reference49 articles.

1. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout

2. Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans